专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007043064A1 A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译：癌症的诊断标记和治疗目标
公开(公告)号：WO2007043064A1
公开(公告)日：2007-04-19
申请号：PCT/IN2006/000402
申请日：2006-10-06
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , CHANDRA, Harish , MUKHERJEE, Rama , BURMAN, Anand, C.
发明人： MAITHAL, Kapil , CHANDRA, Harish , MUKHERJEE, Rama , BURMAN, Anand, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： The present invention, in general, relates to use of nm23H1-B gene for diagnosing cancer susceptibility and metastatic progression in colon/colorectal cancer. In particular, the present invention relates to identifying the alteration in the expression of nm23H1-B gene on treatment with chemotherapeutic agents for diagnosing cancer susceptibility and metastatic progression in colon/colorectal cancer.
摘要翻译：本发明一般涉及nm23H1-B基因用于诊断结肠/结肠直肠癌中的癌症易感性和转移进展。特别地，本发明涉及鉴定nm23H1-B基因在用化学治疗剂治疗结肠/结肠直肠癌中的癌症易感性和转移进展的诊断方面的改变。

2. 发明申请

WO2008114274A1 PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS 审中-公开
标题翻译：脂肪组织和脂肪组成
公开(公告)号：WO2008114274A1
公开(公告)日：2008-09-25
申请号：PCT/IN2008/000003
申请日：2008-01-04
申请人： DABUR PHARMA LIMITED , KHATTAR, Dhiraj , KUMAR, Mukesh , GARG, Minakshi , MUKHERJEE, Rama , BURMAN, Anand, C. , JAGGI, Manu , SINGH, Anu, T. , AWASTHI, Anshumali
发明人： KHATTAR, Dhiraj , KUMAR, Mukesh , GARG, Minakshi , MUKHERJEE, Rama , BURMAN, Anand, C. , JAGGI, Manu , SINGH, Anu, T. , AWASTHI, Anshumali
IPC分类号： A61K9/127 , A61K31/337
CPC分类号： A61K31/337 , A61K9/0019 , A61K9/1271 , A61K9/1277
摘要： Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≥ 95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.
摘要翻译：水溶性差的药物和化合物的浓缩物或前体组合物，包含一种或多种形成膜的脂质，膜稳定剂，在合适的载体中，并且任选地含有聚乙二醇（PEG） - 偶联的磷脂或其混合物，任选地含有药学上可接受的赋形剂如抗氧化剂，缓冲剂，酸化剂等，其具有优异的长期稳定性。促乳素体组合物的浓缩物立即形成所述不良水溶性药物和化合物的脂质体，其快速注射至稀释液体，所得脂质体组合物的特征在于物理稳定性超过24小时，= 95％药物包封并具有粒度直径小于100nm。如此获得的脂质体组合物可以进一步直接施用于需要治疗不良水溶性药物和化合物的患者。

3. 发明申请

WO2007074476A1 A BIOCOMPATIBLE, NON-BIODEGRADABLE, NON-TOXIC POLYMER USEFUL FOR NANOPARTICLE PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：一种可生物降解的，非生物降解的非毒性聚合物，用于纳米脂肪药物组合物
公开(公告)号：WO2007074476A1
公开(公告)日：2007-07-05
申请号：PCT/IN2006/000504
申请日：2006-12-26
申请人： DABUR PHARMA LIMITED , BURMAN, Anand, C. , MUKHERJEE, Rama , KHATTAR, Dhiraj , MULLICK, Sanjoy , JAGGI, Manu , SINGH, Manoj, Kumar , KUMAR, Mukesh , PRUSTHY, Deepak , GUPTA, Pawan, Kumar , PRAVEEN, Rajendran , SINGH, Shobhit
发明人： BURMAN, Anand, C. , MUKHERJEE, Rama , KHATTAR, Dhiraj , MULLICK, Sanjoy , JAGGI, Manu , SINGH, Manoj, Kumar , KUMAR, Mukesh , PRUSTHY, Deepak , GUPTA, Pawan, Kumar , PRAVEEN, Rajendran , SINGH, Shobhit
IPC分类号： C08F220/00
CPC分类号： A61K47/32 , C08F220/56 , C08F222/12 , C08F222/385 , C08F226/10
摘要： The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside adminstration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.
摘要翻译：本发明涉及式（I）的生物相容性，不可生物降解的和无毒的聚合物，其包含三种选自1-乙烯基吡咯烷酮（VP），N-异丙基丙烯酰胺（NIPAM）和马来酸酐的单体单元和与双官能乙烯基衍生物交联的聚乙二醇（MPEG），其纯度高，基本上不含有毒的单体污染物及其制备方法。本发明还涉及难溶于水的药物或包含本发明的聚合物的化合物的纳米颗粒药物组合物，其对于有需要的患者的床边给药是安全的，毒性较小的和方便的。此外，本发明涉及用于制备难溶于水的药物或化合物的纳米颗粒药物组合物的高选择性方法。

4. 发明申请

WO2006106528A1 NOVEL PEPTIDES USEFUL FOR TREATMENT OF ALOPECIA 审中-公开
标题翻译：用于治疗ALOPECIA的新型肽
公开(公告)号：WO2006106528A1
公开(公告)日：2006-10-12
申请号：PCT/IN2005/000453
申请日：2005-12-30
申请人： DABUR PHARMA LIMITED , SINGH, Anu, T. , PRASAD, sudhanand , DATTA, Kakali , AHUJA, Rinku , MUKHERJEE, Rama , BURMAN, Anand, C.
发明人： SINGH, Anu, T. , PRASAD, sudhanand , DATTA, Kakali , AHUJA, Rinku , MUKHERJEE, Rama , BURMAN, Anand, C.
IPC分类号： C07K5/08 , A61K47/18 , A61K38/06 , A61P17/14 , A61Q7/00
CPC分类号： A61K8/44 , A61K38/00 , A61Q7/00
摘要： The invention provides novel peptides of formula (I) and its pharmaceutically acceptable salts thereof and a method of in vitro and in vivo bioassay of the said peptides for promotion and stimulation of hair growth and thereby their usefulness for treatment of alopecia. The invention also provides a method for preparation of the novel peptides of formula (I) and its pharmaceutically acceptable salts thereof as well as a pharmaceutical composition comprising an effective amount of one or more of the novel peptides for promotion and stimulation of hair growth.
摘要翻译：本发明提供式（I）的新颖肽及其药学上可接受的盐，以及所述肽的体外和体内生物测定方法，用于促进和刺激毛发生长，从而提高其对脱发的治疗效果。本发明还提供了制备式（I）的新肽及其药学上可接受的盐的方法以及包含有效量的一种或多种用于促进和刺激毛发生长的新肽的药物组合物。

5. 发明申请

WO2006085336A3 STABILIZED ANTHRACYCLINE GLYCOSIDE PHARMACEUTICAL COMPOSITIONS 审中-公开
公开(公告)号：WO2006085336A3
公开(公告)日：2006-08-17
申请号：PCT/IN2006/000010
申请日：2006-01-16
申请人： DABUR PHARMA LIMITED , UPADHYAY, Satish, Chandra , PANANCHUKUNNATH, Manoj, Kumar , SINGH, Ajeet, Kumar , JAIN, Deepti , PARSHOTTAMDAS, Deepak, Judgelal , MUKHERJEE, Rama , BURMAN, Anand, C
发明人： UPADHYAY, Satish, Chandra , PANANCHUKUNNATH, Manoj, Kumar , SINGH, Ajeet, Kumar , JAIN, Deepti , PARSHOTTAMDAS, Deepak, Judgelal , MUKHERJEE, Rama , BURMAN, Anand, C
IPC分类号： A61K47/48 , A61K9/00
摘要： A stable pharmaceutical composition comprising an anthracycline glycoside in an aqueous solvent is disclosed. The composition optionally includes an inert gas.

6. 发明申请

WO2006085334A3 NOVEL BETULINIC ACID DERIVATIVES A-RING-CONDENSED TO A HETEROCYCLIC GROUP 审中-公开
公开(公告)号：WO2006085334A3
公开(公告)日：2006-08-17
申请号：PCT/IN2005/000445
申请日：2005-12-29
申请人： DABUR PHARMA LIMITED , MUKHERJEE, Rama , SRIVASTAVA, Sanjay, Kumar , SIDDIQUI, Mohammad, Jamshed, Ahmed , JAGGI, Manu , SINGH, Anu, T. , VARDHAN, Anand , SINGH, Manoj, Kumar , RAJENDRAN, Praveen , JAJOO, Hemant, Kumar , BURMAN, Anand, C. , KUMAR, Vivek , RANI, Nidhi , AGARWAL, Shiv, Kumar
发明人： MUKHERJEE, Rama , SRIVASTAVA, Sanjay, Kumar , SIDDIQUI, Mohammad, Jamshed, Ahmed , JAGGI, Manu , SINGH, Anu, T. , VARDHAN, Anand , SINGH, Manoj, Kumar , RAJENDRAN, Praveen , JAJOO, Hemant, Kumar , BURMAN, Anand, C. , KUMAR, Vivek , RANI, Nidhi , AGARWAL, Shiv, Kumar
IPC分类号： C07J71/00 , A61K31/58 , A61P35/00
摘要： The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C (=CH 2 ) CH 3 or CH(CH 3 ) 2 ; R 2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R 3 or R 4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R 3 and R 4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R 1 is zero when Y is O, and R 1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells. Formula (I)

7. 发明申请

WO2007072504A1 DNA VACCINE FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的DNA疫苗
公开(公告)号：WO2007072504A1
公开(公告)日：2007-06-28
申请号：PCT/IN2006/000497
申请日：2006-12-19
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , SENGUPTA, Paromita , MUKHERJEE, Rama
发明人： MAITHAL, Kapil , SENGUPTA, Paromita , MUKHERJEE, Rama
IPC分类号： A61K39/00 , C12N15/62 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/55516 , A61K2039/57 , A61K2039/6031 , C07K14/57563 , C07K14/705 , C07K14/71 , C07K2319/01 , C12N9/93
摘要： The invention relates to a fusion gene useful as a therapeutic and prophylactic vaccine against cancer. The fusion gene contains a DNA encoding ubiquitin gene fused to a second DNA encoding growth factor receptors or fragment thereof, over expressed in various types of cancer. In particular, the invention is illustrated by a recombinant fusion gene comprised of mutated ubiquitin gene and modified extra cellular domain of vasoactive intestinal peptide/ pituitary adenylate cyclase activating polypeptide receptor-1 (VPACl). Immunization with the vaccine will break the self- tolerance for the tumor antigen through effective antigen processing and presentation, leading to retardation/ regression of tumor growth.
摘要翻译：本发明涉及可用作抗癌治疗和预防性疫苗的融合基因。该融合基因含有编码泛素基因的DNA，其与编码生长因子受体或其片段的第二个DNA融合，在多种类型的癌症中表达。特别地，通过由突变的泛素基因和血管活性肠肽/垂体腺苷酸环化酶活化多肽受体-1（VPAC1）的修饰的超细胞结构域组成的重组融合基因来说明本发明。用疫苗免疫将通过有效的抗原加工和呈递来破坏肿瘤抗原的自身耐受性，导致肿瘤生长的延迟/消退。

8. 发明申请

WO2007057922A1 TARGETED FUSION PROTEINS FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的目标融合蛋白
公开(公告)号：WO2007057922A1
公开(公告)日：2007-05-24
申请号：PCT/IN2006/000452
申请日：2006-11-16
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , NACHIAPPAN, Dhatchana, Moorthy , MUKHERJEE, Rama
发明人： MAITHAL, Kapil , NACHIAPPAN, Dhatchana, Moorthy , MUKHERJEE, Rama
IPC分类号： C07K14/435 , A61K38/17
CPC分类号： A61K38/1709
摘要： The invention relates to fusion proteins useful as therapeutics against cancer. The fusion protein comprises of cell-targeting moiety and apoptosis-inducing moiety. Cell-targeting moiety and apoptosis-inducing moiety are linked by a flexible linker, which are specifically recognized by cancer specific protease and cleaved in situ to release the apoptotic domain. In particular, the invention is illustrated by a recombinant fusion protein between human Vasoactive Intestinal Peptide (VIP) and BH3 domain of Bcl2 family protein, linked by a linker that has site for cancer specific proteases. The fusion protein specifically targets VIP receptor over-expressing cancer cells and induces cell-specific apoptosis after cleavage at the linker site by cancer specific proteases. Such fusion proteins are useful for the delivery of therapeutic/apoptotic moiety (peptides) to specific cells with perturbed expression of, but not limited to neuropeptide receptors.
摘要翻译：本发明涉及可用作抗癌药物的融合蛋白。融合蛋白包含细胞靶向部分和凋亡诱导部分。细胞靶向部分和凋亡诱导部分通过柔性接头连接，柔性接头被癌特异性蛋白酶特异性识别并原位切割以释放凋亡结构域。特别地，本发明由人血管活性肽（VIP）和Bcl2家族蛋白的BH3结构域之间的重组融合蛋白说明，其通过具有癌症特异性蛋白酶位点的接头连接。融合蛋白特异性靶向VIP受体过表达癌细胞，并通过癌特异性蛋白酶在连接位点切割后诱导细胞特异性凋亡。这种融合蛋白可用于将治疗性/凋亡部分（肽）递送至具有神经肽受体的扰动表达但不限于特异性细胞。

9. 发明申请

WO2003004469A1 ANTICANCER ACTIVITY OF IMINO ACID CONJUGATES OF METHYLGLYOXAL 审中-公开
标题翻译：氨基甲酸的氨基酸结合物的反应活性
公开(公告)号：WO2003004469A1
公开(公告)日：2003-01-16
申请号：PCT/US2002/020753
申请日：2002-07-01
申请人： DABUR RESEARCH FOUNDATION , CORD, Janet, I. , BURMAN, Anand, C. , MUKHERJEE, Rama , JAGGI, Manu , SINGH, Anu, T. , KAPOOR, Kamal, K. , PRASAD, Sudhanand , RAY, Manju Indian Institute of Cultivation of Science
发明人： BURMAN, Anand, C. , MUKHERJEE, Rama , JAGGI, Manu , SINGH, Anu, T. , KAPOOR, Kamal, K. , PRASAD, Sudhanand , RAY, Manju Indian Institute of Cultivation of Science
IPC分类号： C07D207/28
CPC分类号： C07D207/28
摘要： The invention relates to the use of imino acid conjugates of methylglyoxal (I) for the inhibition and/or treatment of cancer. The invention relates more specifically to the use imino acid conjugates of methylglyoxal (I) for inhibition and/or treatment of cancer of the Colon, Prostate, Larynx, Kidney, Pancreas, Lung,Breast, Intestine, Oral Cavity, Ovary, Gliobastoma, and Leukemia. The invention also relates to compositions and methods of inhibiting cancer using imino acid conjugates of methylglyoxal (I).
摘要翻译：本发明涉及甲基乙二醛（I）的亚氨基酸缀合物用于抑制和/或治疗癌症的用途。本发明更具体地涉及使用甲基乙二醛（I）的亚氨基酸偶联物用于抑制和/或治疗结肠，前列腺，喉，肾，胰腺，肺，乳腺，肠，口腔，卵巢，胶质母细胞瘤和白血病。本发明还涉及使用甲基乙二醛（I）的亚氨基酸缀合物抑制癌症的组合物和方法。

10. 发明申请

WO2005017079A1 PROCESS FOR THE PURIFICATION OF NON-IONIC SOLVANTS FOR STABILIZED INJECTABLE PHARMACEUTICAL FORMULAITONS 审中-公开
标题翻译：用于稳定的可注射药物制剂的非离子溶剂的纯化方法
公开(公告)号：WO2005017079A1
公开(公告)日：2005-02-24
申请号：PCT/US2003/023243
申请日：2003-07-24
申请人： DABUR RESEARCH FOUNDATION , CORD, Janet, I. , BURMAN, Anand, C. , MUKHERJEE, Rama , KUMAR, Dinesh , KHATTAR, Dhiraj , KHULLER, Praveen , SRINIVASAN, PS , SRIVASTAVA, Rajesh
发明人： BURMAN, Anand, C. , MUKHERJEE, Rama , KUMAR, Dinesh , KHATTAR, Dhiraj , KHULLER, Praveen , SRINIVASAN, PS , SRIVASTAVA, Rajesh
IPC分类号： C11B3/00
CPC分类号： A61K9/0019 , A61K47/44
摘要： A stabilized pharmaceutical composition of anticancer drug and a solvent like Polyethoxylated castor oil (cremophor) also containing any other suitable solubilizer suitable for human administration like dehydrated alcohol, is disclosed. Compositions prepared using this purified polyethoxylated castor oil enhance the stability of paclitaxel in such compositions.
摘要翻译：公开了一种稳定的抗癌药物和溶剂，如聚乙氧基化蓖麻油（cremophor）的药物组合物，其还含有适于人类给药的任何其它合适的增溶剂如脱水醇。使用该纯化的聚乙氧基化蓖麻油制备的组合物增强紫杉醇在这些组合物中的稳定性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式